Androgen deprivation therapy (ADT) for treating metastatic prostate cancer patients is effective only initially and, therefore, secondary hormonal therapies are examined for suppressing AR reactivation in CRPC, requiring reliable biomarkers to guide their application since responses to AR pathway inhibitors vary significantly. The gene discussed is AR; the disease is metastatic prostate carcinoma.